Protalix Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on July 2, 2021. The filing details the entry into a new material definitive agreement for an equity offering and the termination of a prior sales agreement.
Key Financial Metrics and Capital Activities
- New Offering Capacity: Entered into an At-The-Market (ATM) Sales Agreement with H.C. Wainwright & Co., LLC to sell up to $20,000,000 of common stock.
- Prior Offering Results: Terminated the previous ATM agreement with BofA Securities, Inc. (dated October 1, 2020). Under that agreement, the Company sold 3,296,123 shares for total gross proceeds of approximately $13.8 million.
- Use of Proceeds: Net proceeds from the new offering are intended for general corporate purposes.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, or debt data. Refer to the Company's Form 10-K or 10-Q for comprehensive financial metrics.
Material Changes
The primary material change is the replacement of the Company's sales agent for its ATM program. The Company terminated its agreement with BofA Securities, Inc. and simultaneously executed a new agreement with H.C. Wainwright & Co., LLC, reducing the authorized offering size from $30,000,000 to $20,000,000 for the new facility.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the Company's expectations and plans. Management cautions that actual results may differ materially due to known and unknown risks. Specific risks are detailed in the Company's Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the current cash position and burn rate in the most recent Form 10-Q to assess the necessity of the new $20 million ATM facility.
- Review the full text of the Sales Agreement (Exhibit 1.1) for commission rates and termination clauses.
- Monitor future filings for actual sales volumes and pricing under the new H.C. Wainwright agreement.
- Check the Company's Form 10-K for updated risk factors related to capital raising and liquidity.